score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline	Guideline		Copy Number	AR	Amplification				0.0	0.0		Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf	Putatively Actionable	Abiraterone	Hormone therapy	Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.	National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf						0				AR Amplification		SC_9093	SC_9093-TM	
Putatively Actionable	Preclinical	Preclinical		Copy Number	MIR17HG	Deletion				0.0	0.0		Investigate Actionability - Low	Neoadjuvant chemotherapy + surgery	Combination therapy	Amplification of the 13q31-34 region, which contains MIR17HG, was associated with increased sensitivity to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.	Molinari C, Salvi S, Foca F, et al. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 2016;9:2735-42.	https://doi.org/10.2147/OTT.S105760	Putatively Actionable	Neoadjuvant chemotherapy + surgery	Combination therapy	Deletion of the 13q31-34 region, which contains MIR17HG, was associated with resistance to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.	Molinari C, Salvi S, Foca F, et al. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 2016;9:2735-42.	https://doi.org/10.2147/OTT.S105760						0				MIR17HG Deletion		SC_9093	SC_9093-TM	
Putatively Actionable	Inferential		Clinical evidence	Copy Number	CCND1	Amplification				0.0	0.0		Putatively Actionable	Palbociclib	Targeted therapy	CCND1 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744							Putatively Actionable	0.0	CCND1 amplification showed reduced recurrence-free survival in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506	0				CCND1 Amplification	1.0	SC_9093	SC_9093-TM	
Investigate Actionability - High	FDA-Approved			Rearrangement	FIP1L1	Fusion	FIP1L1--FAAH			0.0	0.0		Investigate Actionability - High	Imatinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with chronic eosinophilic leukemia (CEL) who have FIP1L1-PDGFRA fusions.	Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf												0				FIP1L1--FAAH Fusion	0.0	SC_9093		
Investigate Actionability - High	FDA-Approved			Rearrangement	FIP1L1	Fusion	NDUFB6--FIP1L1			0.0	0.0		Investigate Actionability - High	Imatinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with chronic eosinophilic leukemia (CEL) who have FIP1L1-PDGFRA fusions.	Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf												0				NDUFB6--FIP1L1 Fusion	0.0	SC_9093		
Investigate Actionability - High	Guideline			Rearrangement	COL1A1	Fusion	LRRC32--COL1A1			0.0	0.0		Investigate Actionability - High	Imatinib	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf												0				LRRC32--COL1A1 Fusion	0.0	SC_9093		
Investigate Actionability - High	Preclinical			Rearrangement	ESRP1	Fusion	ESRP1--PABPC1			0.0	0.0		Investigate Actionability - High	Sorafenib	Targeted therapy	Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.	Palanisamy N, Ateeq B, Kalyana-sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793-8.	https://doi.org/10.1038/nm.2166												0				ESRP1--PABPC1 Fusion	1.0	SC_9093		
Investigate Actionability - High	Preclinical			Somatic Variant	MET	Missense	p.T1307I	0.2198	182.0	0.0	0.0		Investigate Actionability - High	SU11274	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881												0	0.0	0.0	0.0	MET p.T1307I (Missense)	0.0	SC_9093	SC_9093-TM	SC_9093-NB
Investigate Actionability - High		Clinical evidence		Somatic Variant	AR	Missense	p.Q59L	0.0092	759.0	0.0	0.0								Investigate Actionability - High	Abiraterone	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0	2844.0	0.006	0.9997	AR p.Q59L (Missense)		SC_9093	SC_9093-TM	SC_9093-NB
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						SC_9093		
Investigate Actionability - Low	Preclinical			Rearrangement	BRAF	Fusion	BRAF--RNF38			0.0	0.0		Investigate Actionability - Low	Sorafenib	Targeted therapy	Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.	Palanisamy N, Ateeq B, Kalyana-sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793-8.	https://doi.org/10.1038/nm.2166												0				BRAF--RNF38 Fusion	0.0	SC_9093		
Investigate Actionability - Low	Preclinical			Rearrangement	BRAF	Fusion	LSM12--BRAF			0.0	0.0		Investigate Actionability - Low	Sorafenib	Targeted therapy	Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.	Palanisamy N, Ateeq B, Kalyana-sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793-8.	https://doi.org/10.1038/nm.2166												0				LSM12--BRAF Fusion	0.0	SC_9093		
Investigate Actionability - Low	Preclinical			Rearrangement	BRD4	Fusion	PTMS--BRD4			0.0	0.0		Investigate Actionability - Low	JQ1	Targeted therapy	BET inhibition was found to have an antitumor effect in a murine model of squamous cell carcinoma.	Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-73.	https://doi.org/10.1038/nature09504												0				PTMS--BRD4 Fusion	0.0	SC_9093		
Investigate Actionability - Low	Preclinical			Rearrangement	BRD4	Fusion	NAPB--BRD4			0.0	0.0		Investigate Actionability - Low	JQ1	Targeted therapy	BET inhibition was found to have an antitumor effect in a murine model of squamous cell carcinoma.	Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-73.	https://doi.org/10.1038/nature09504												0				NAPB--BRD4 Fusion	0.0	SC_9093		
Investigate Actionability - Low		Clinical evidence	Clinical trial	Somatic Variant	TP53	Deletion	p.CPHH176del	0.7133	150.0	0.0	0.0								Investigate Actionability - Low	Lenalidomide	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability - Low	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0	0.0	0.0	0.0	TP53 p.CPHH176del (Deletion)		SC_9093	SC_9093-TM	SC_9093-NB
Biologically Relevant				Rearrangement	AR	Fusion	AR--ITM2B			0.0	0.0																			0				AR--ITM2B Fusion		SC_9093		
Biologically Relevant				Rearrangement	AR	Fusion	H19--AR			0.0	0.0																			0				H19--AR Fusion		SC_9093		
Biologically Relevant				Rearrangement	SMARCA4	Fusion	SMARCA4--SLK			0.0	0.0																			0				SMARCA4--SLK Fusion		SC_9093		
Biologically Relevant				Rearrangement	BARD1	Fusion	TM7SF3--BARD1			0.0	0.0																			0				TM7SF3--BARD1 Fusion		SC_9093		
Biologically Relevant				Rearrangement	ARID1A	Fusion	RNF13--ARID1A			0.0	0.0																			0				RNF13--ARID1A Fusion		SC_9093		
Biologically Relevant				Rearrangement	CTNNB1	Fusion	MALAT1--CTNNB1			0.0	0.0																			0				MALAT1--CTNNB1 Fusion		SC_9093		
Biologically Relevant				Rearrangement	RBM10	Fusion	KDM4B--RBM10			0.0	0.0																			0				KDM4B--RBM10 Fusion		SC_9093		
Biologically Relevant				Copy Number	EZH2	Amplification				0.0	0.0																			0				EZH2 Amplification		SC_9093	SC_9093-TM	
Biologically Relevant				Copy Number	MC1R	Deletion				0.0	0.0																			0				MC1R Deletion		SC_9093	SC_9093-TM	
Biologically Relevant				Copy Number	FLCN	Deletion				0.0	0.0																			0				FLCN Deletion		SC_9093	SC_9093-TM	
Biologically Relevant				Microsatellite Stability	Supporting variants		ESRP1--PABPC1 Fusion, PVRL3--MSH3 Fusion, PRDM2 p.703_704insP (Insertion), MSH3 p.-59fs (Frameshift), MSH3 p.A61fs (Frameshift)																							0				Supporting variants: ESRP1--PABPC1 Fusion, PVRL3--MSH3 Fusion, PRDM2 p.703_704insP (Insertion), MSH3 p.-59fs (Frameshift), MSH3 p.A61fs (Frameshift)		SC_9093		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.658																							0				COSMIC Signature 1 (66%)		SC_9093		
Biologically Relevant				Mutational Signature	COSMIC Signature 15		0.298																							0				COSMIC Signature 15 (30%)		SC_9093		
